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A 52-year-old man sought advice for progressive stiffness of
joints and weakness. He had been treated with chronic hemo-
dialysis for the previous 10 years for renal failure due to
glomerulosclerosis. He was receiving his hemodialysis treat-
ments at a dialysis center that had begun using water treated by
reverse osmosis only in the previous year. The majority of
dialysis sessions were carried out utilizing reused, hollow-fiber,
cuprophane dialyzers. No major complications had been asso-
ciated with his hemodialysis therapy, although he did have a
history of frequent skin infection due to Staphylococcus au-
reus. He was antibody-negative for hepatitis B surface antigen
despite two attempts to immunize him using the naturally
derived vaccine Heptavax-B (Merck Sharp & Dohme). Medi-
cations included aluminum hydroxide, vitamin D3, ranitidine,
and ibuprofen.
Physical examination revealed a pale white man who ap-
peared older than his age. The skin was dry and wrinkled. The
lungs were clear and a grade Il/VI precordial flow murmur was
audible. No hepatosplenomegaly or lymphadenopathy was ap-
parent. He had a positive Tinel sign. The remainder of the
physical examination was unremarkable. Laboratory results
revealed a hematocrit of 32% and a white blood cell count of
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4800/mm3 with lymphopenia. Carpal-tunnel syndrome was di-
agnosed.
Discussion
Da. CHARLES A. DINARELLO (Professor of Medicine and
Pediatrics, Tufts University School of Medicine and the New
England Medical Center, Boston, Massachusetts): Although
significant advances have been made in correcting the electro-
lyte, fluid, and metabolic imbalances of hemodialysis, the basic
nature of chronic hemodialysis-related changes in immune and
host-defense systems remains unclear. The fundamental issue
in this discussion concerns the effects of chronic hemodialysis
on cytokine production by the peripheral blood mononuclear
cell population. These cells comprise monocytes, natural killer
cells, and T lymphocytes. Mononuclear cells can be stimulated
to release cytokines by complement activation by the dialyzer,
by the interaction of dialyzer polymer materials, by microbial
products diffusing into the blood compartment from the dialysis
bath, and by the mechanical pumping of blood in the hemodi-
alysis circuit. Monocytes that circulate in the peripheral blood
are easily stimulated by these hemodialysis-related events to
produce polypeptide cytokines. Of the more than 20 cytokines
produced by the circulating mononuclear cell population, only a
few have been studied in relation to hemodialysis; these are
interleukin-l (IL-1), IL-2, interferon (a and y), IL-6, and tumor
necrosis factor (TNF); of these, IL-i and TNF are potent
inducers of inflammatory changes, and their production during
or after hemodialysis is an important consideration in the
pathogenesis of inflammation.
Some hemodialysis procedures can result in the synthesis of
these cytokines, but what role does acute or chronic cytokine
production play in the pathogenesis of some hemodialysis-
related diseases? For example, do cytokines account for the
elevated temperature following hemodialysis [1]? Is the hypo-
tension associated with the hemodialysis procedure due to
cytokines? Does chronic cytokine production contribute to
immune dysfunction? Can chronic cytokine production explain
the increased susceptibility to infection or to atherosclerosis?
Moreover, interactions between the cytokines, which can be
either synergistic or antagonistic, complicate interpretation of
the data. For example, interferons can inhibit some actions of
IL- 1, but they augment the ability of TNF to induce HLA gene
expression. Also, immunologic dysfunction, as evidenced by a
low antibody response to hepatitis-B vaccination, and degener-
ative changes can be observed in patients with end-stage renal
disease (ESRD) whether or not they have been treated with
hemodialysis [2}. Some studies have shown differences among
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immunologic dysfunctions in patients with severe renal failure,
patients treated with continuous ambulatory peritoneal dialysis
(CAPD), and those undergoing chronic hemodialysis [3]. Im-
mune dysfunction is well documented in hemodialysis patients,
particularly after a few years of treatment [4].
In this discussion, I will review the biology of IL-i and TNF,
particularly emphasizing the inflammatory properties of these
cytokines. Then I will discuss laboratory studies on cytokine
production that are relevant to hemodialysis. These are: (1)
studies on the ability of cytokine-inducing microbial substances
that cross the dialysis membrane and enter the blood compart-
ment; (2) the role of complement activation; (3) cytokine levels
in the circulation during hemodialysis; and (4) production of
cytokines in patients treated with hemodialysis. The discussion
will conclude with a review of two natural mechanisms that
oppose the biologic activities of IL-i and TNF, that is, soluble
receptors for TNF and the IL-i receptor antagonist.
From my perspective, three directions exist for the improve-
ment of hemodialysis: greater attention to the removal of
cytokine-inducing microbial products from the dialysate; im-
proved hemodialysis membranes, which reduce activation of
mononuclear cells; and the therapeutic use of cytokine antago-
nists as well as some cytokines themselves (for example,
interferons for improved bacterial killing).
Biology of IL-I and TNF
Cytokines are similar to the endocrinologic hormones in that
they are highly potent molecules (active at pico- and femtomo-
lar concentrations) that affect cellular responses distal to their
site of production; the analogy stops there, however. Unlike the
hormones, the primary function of the cytokines appears to be
a response to infection, inflammation, or immune challenge.
Hormones, on the other hand, are primarily involved in main-
taining homeostatic balances. Cytokines are polypeptides with
molecular weights from 10 to 45 kD; they possess a wide
spectrum of immunologic and nonimmunologic activities. Sev-
eral cytokines were originally named for their dominant biologic
effect. For example, after /3-lymphocyte growth factor 2 was
cloned, this molecule was found to be identical to hepatocyte-
stimulating factor. It was then decided to change its name and
now the molecule is termed IL-6. Naming the cytokines has
been disorderly; some cytokines have interleukin nomencla-
ture, whereas others have their original name (for instance,
TNF). The various cytokines can be grouped into 5 broad
classes according to their prominent biologic properties: (1)
inflammatory cytokines; (2) antiinflammatory cytokines; (3)
lymphocyte growth and differentiation factors; (4) hematopoi-
etic colony-stimulating factors; and (5) mesenchymal cell
growth factors. Both IL-I and TNF possess several inflamma-
tory properties. Evidence is increasing that elevated production
of some inflammatory cytokines or of the lymphocyte growth
factors is associated with, or can been a primary cause of, a
particular disease process. It is also likely, however, that
low-level production of some of these same cytokines also
affects the resolution of disease. For example, colony-stimulat-
ing factors play a role in maintaining normal hematopoiesis, but
reduced production of these cytokines impairs host defense
mechanisms against infection.
Long-term hemodialysis often is associated with a more rapid
aging process, a process that also has been related to increased
cytokine production [51. Since the discovery of the cytokines,
particularly the inflammatory cytokines, a number of investiga-
tors have proposed that because of their biologic properties,
these cytokines likely mediate disease. Now that several cyto-
kines have been administered to humans, this concept has
received considerable support. For example, TNF was first
shown to cause a shock-like syndrome [61 in animals; when
injected into humans at low concentrations (less than I p,g/kg),
TNF produced hypotension and leukopenia as well as several
metabolic derangements [7]. A similar case can be made for
IL-i. Interleukin-i produces fever and hypotension in rabbits
[8]; humans receiving only 1 nglkg of IL-i develop fever, and
with increasing doses, hypotension develops [9, 10]. In fact, the
dose-limiting effect of 300 ng/kg of IL-i given intravenously in
humans is hypotension. Smith et at reported stage-IV hypoten-
sion in patients receiving 1 pg/kg [9].
Interleukin-l possesses beneficial as well as detrimental
activities. In some cases, these differences are due to the
concentration of IL-i administered in animal studies or em-
ployed in in vitro experiments. For example, low doses of IL-i
stimulate insulin production, whereas high concentrations in-
hibit insulin transcription and are cytotoxic for the beta cells in
the islets of Langerhans [11, 12]. Indeed, IL-i is thought to play
a role in the pathogenesis of type-i diabetes mellitus. High
concentrations of IL-i suppress testosterone synthesis,
whereas iow concentrations augment production. Other bio-
logic properties of IL-i clearly are beneficial to host defense.
Pre-treatment with a single, low dose of IL-i protects animals
from lethal microbial sepsis, from lung damage due to hyper-
oxia, from inflammatory bowel disease, from bronchial hista-
mine release, from lethal irradiation, and from suppression of
bone marrow function following the administration of antime-
tabolites [13, 14]. Pre-treatment with TNF affords the same
spectrum of protection [15]. Some of the beneficial effects of
IL-i are due to protection of bone marrow stem cells. In fact,
low concentrations of IL-i are being used in humans to stimu-
late hematopoiesis; humans given IL-i respond with elevated
circulating neutrophils and with elevated platelet counts that
remain high for 28 days [10]. Although TNF has a suppressive
effect on hematopoiesis, TNF-induced protection might involve
down regulation of TNF receptor expression [15].
There is little question that IL-i and TNF are the dominant
inflammatory cytokines involved in hemodialysis. Two other
cytokines, namely IL-6 and IL-8, also are relevant to hemodi-
alysis. Similar to IL-i and TNF, IL-6 is an endogenous pyro-
gen; it stimulates hepatic acute-phase proteins; it suppresses
albumin synthesis; and it is a potent T- and B-lymphocyte
growth factor. Interleukin-8, a chemotactic peptide for neutro-
phils, monocytes, and lymphocytes, also activates neutrophil
functions. In addition to triggering events in the central nervous
system that lead to fever, IL-i and TNF also trigger the release
of a variety of neuropeptides, the most important of which are
ACTH, corticotropin releasing factor, and somatostatin. Al-
though IL-i and TNF are appetite suppressants, their mecha-
nism of action as anorectic agents is thought to be due to
peripheral effects on hepatic metabolism rather than to effects
in the central nervous system. Both IL-i and TNF induce a
rapid increase in slow-wave sleep, even before the onset of
fever. One might speculate that the lethargy of patients after
dialysis is due to the effects of these two cytokines.
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Interleukin-l and TNF are highly synergistic both in animal
and in vitro studies. Both these cytokines act synergistically in
producing hemodynamic shock [8], eicosanoid synthesis, and
cell toxicity. A considerable number of biologic responses to
IL-i and TNF are due to their ability to increase gene expres-
sion for cyclooxygenase and phospholipase A2. Within minutes
of exposing cells to either IL-i or TNF, cells dramatically
increase new mRNA coding for cyclooxygenase [16]. In iso-
lated tissues perfused with IL-I, PGE2 increases rapidly in the
perfusate [17, 18]. The synthesis of POE2 and other products of
arachidonic acid cyclooxygenation by vascular and intestinal
tissue continues for several hours after cessation of the cyto-
kine perfusion. As a result of increased PGE2 synthesis, there is
an associated increased pain response to bradykinin [181. The
increased synthesis of lipid metabolites such as the prostaglan-
dins and also of platelet activating factor by IL-i and TNF
contribute to the shock syndrome [19]. Hypotension, neutrope-
nia, thrombocytopenia, lactic acidosis, and decreased systemic
vascular resistance all occur following an intravenous injection
of a combination of TNF and IL-i [8]. Interleukin-1 plus TNF
enhance endothelial coagulant activity, the expression of leu-
kocyte adhesion molecules, and synthesis of a plasminogen
activator inhibitor.
Synovial tissues removed from patients with rheumatoid
arthritis actively produce IL-l, TNF, and POE2. Collagenase
production by these cells is thought to be due to cells activated
in vivo to produce these cytokines. Production of IL-6 and IL-8
also is elevated in synovial cells. Interleukin-l and TNF stim-
ulate osteoblasts, and bone loss is associated with IL-I and
TNF production. It is therefore not surprising that inhibitors of
cyclooxygenase, such as aspirin or nonsteroidal antiinflamma-
tory agents, are useful in diseases thought to be mediated by
IL-l and TNF. Clearly this is a major strategy of antiinflamma-
tory drug therapy. However, agents that block the ability of
IL-I and TNF to induce cyclooxygenase gene expression have
a higher therapeutic index, because such antagonists do not
interfere with cyclooxygenation in gastric tissue or platelets.
For example, agents that block IL-i and TNF binding to their
respective cellular receptors are highly specific for cytokine-
mediated inflammatory responses but spare the "household"
cyclooxygenation of arachidonic acid. Two such agents are the
IL-I receptor antagonist (IL-ira) and the TNF-binding proteins.
I'll return to these agents later.
Not all properties of IL-i or TNF are mediated through their
ability to increase cyclooxygenase and phospholipase A2 syn-
thesis. The most consistent properties of IL-I and TNF are
upregulation of cellular metabolism and increased expression of
several genes coding for biologically active molecules. But
some genes, particularly "household" genes, are suppressed by
IL-i, IL-6, and TNF. For example, those suppressed are genes
for albumin, lipoprotein lipase, cytochrome P450, and aro-
matase. Interleukin-1 and TNF predominantly activate tran-
scription of several genes but also stabilize mRNA for others,
and both events lead to increased new protein synthesis. In the
liver, IL-i, TNF, and IL-6 upregulate the transcription of
several hepatic acute-phase proteins such as a2-acid glycopro-
tein and a2-macroglobulin. Interleukin- 1 also initiates the tran-
scription of serum amyloid A; this is a direct effect of IL-I on
hepatocytes, but other effects of IL-I on hepatic protein syn-
thesis are due to IL-l-induced IL-6 production. Interleukin-1 is
Table 1. Comparison of IL-i, TNF, and IL-6
Biologic property IL-I TNF IL-6
Endogenous pyrogen fever + + +
Slow-wave sleep + + —
Hepatic acute-phase proteins + + +
T cell activation + -i- +
B cell activation + + +
B cell Ig synthesis — — +
Fibroblast proliferation + + —
Stem cell activation (hemopoietin-l) + — +
Nonspecific resistance to infection + + +
Radioprotection + + —
Cyclooxygenase, PLA2 gene + + —
expressiona
Synovial cell activation + + —
Endothelial cell activation + +
Shock syndrome + + —
Induction of IL-I, TNF, and IL-8 + + —
Induction of IL-6 + + —
a PLA, phospholipase A.
a potent inducer of IL-6 in fibroblasts and other cells; in fact, in
animals given an inflammatory agent such as turpentine, pre-
treatment with an antibody to the IL-i receptor blocks IL-6
synthesis and reduces the acute phase response.
Table I compares the biologic properties of IL-I, TNF, and
IL-6. Although IL-6 causes fever and stimulates hepatic protein
synthesis, IL-6 does not stimulate endothelial cells to express
adhesion molecules or other parameters of inflammation. Inter-
leukin-6 also does not increase cyclooxygenase expression, and
large doses of IL-6 do not cause hypotension. Unlike IL-i and
TNF, IL-6 is not a growth factor for fibroblasts and does not
stimulate bone resorption or collagen breakdown. In fact, IL-6
suppresses fibroblast proliferation. Also, IL-6 suppresses gene
expression and synthesis for IL-i and TNF [201. In comparison
to IL-i and TNF, IL-6 is an antiinflammatory cytokine. Its role
in the production of fever and the hepatic synthesis of acute-
phase proteins, however, should not be underestimated. One
interpretation is that the IL-6-induced synthesis of hepatic
acute-phase proteins is a manifestation of the antiinflammatory
properties of this cytokine. Finally, interleukin-i and TNF
block gene expression for lipoprotein lipase while increasing
hepatic fatty acid synthesis [21, 221.
Laboratory studies on cytokine production during
hemodialysis
Interest in the role of IL-i, IL-6, and TNF in patients
undergoing hemodialysis (Fig. 1) began because the fever of
dialysis was attributed to pyrogenic contamination of the dial-
ysate. Indeed, before the introduction of reverse-osmosis water
purification, endotoxin contamination of dialysate was a prob-
lem, particularly in areas of the world where tap-water sources
were impure. Recent surveys of the incidence of pyrogenic
reactions during hemodialysis, including patients treated with
hemodialysis using high-flux membranes, demonstrate a low
incidence compared with that during the early days of hemodi-
alysis [23]. However, the prevailing wisdom in those days was
based on the failure to demonstrate convincingly the passage of
pyrogenic materials across the cuprophane membrane despite
the clinical association of dialysate contamination and fever. In
a series of animal experiments using fever as an indicator of
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Fig. 1. Cytokine induction during hemodialysis.
endotoxin passage into the blood compartment, Port and Ber-
nick could not demonstrate that such passage occurred 1241.
These studies utilized the rabbit pyrogen test, which then was
considered a highly reliable test for the detection of pyrogens.
With the availability of the sensitive Limulus amebocyte lysate
(LAL) test for endotoxins (10 pg/mI for the LAL versus 10
nglkg for the rabbit pyrogen test), the concept that endotoxins
did not cross the cuprophane membrane was reinforced by a
consistent inability to show LAL reactivity in the blood corn-
partment of in vitro dialysis circuits challenged with large
amounts of endotoxins; the restrictive pore size of the mem-
brane was offered as explanation. Even using high-flux mem-
branes with apparently large pores, the LAL test continues to
indicate that endotoxic pyrogens do not cross the membrane.
Passage of cytokine-inducing materials from the dialysate.
To determine whether substances that induced cytokines were
responsible for hemodialysis-associated fever, experiments us-
ing an in vitro model of hemodialysis have been employed. The
new experiments were based on the hypothesis that monocyte
activation for IL-l production was more relevant in hemodial-
ysis than was LAL reactivity. In the initial experiments, fresh,
heparinized human blood was circulated through a closed-
circuit dialyzer, and the dialysate compartment was challenged
with either pyrogen-free saline or saline that was purposefully
contaminated with purified lipopolysaccharide (LPS) extracted
from E. co/i. After 4 hours of circulation through a cuprophane
membrane, the blood was removed, and the mononuclear cells
were separated and then incubated for 24 hours. When the
dialysate was filled with pyrogen-free saline, the cells did not
increase IL-I production significantly; when the dialysate was
filled with LPS-containing saline (1 ig/ml), however, the mono-
nuclear cells were stimulated to produce IL-l [25].
Other experiments were designed to identify whether endo-
toxin-like substances pass across the membrane; an endotoxin-
like material is one that reacts with the cationic peptide poly.
myxin B. We circulated a mixture of 10% fresh human plasma
with tissue-culture medium in the blood compartment and
challenged the dialysate with a filtrate of whole, live E. co/i
organisms [261. Samples from the blood compartment were
taken and added to human mononuclear cells. After 24 hours of
incubation, we assessed IL-I production by those cells. Sam-
ples taken from the blood compartment 15 minutes after the
introduction of bacterial filtrates stimulated IL-i production.
These studies demonstrated that endotoxin-like activity does
pass the intact cuprophane membrane and can stimulate IL-l
production. Since the IL-I-inducing activity found in the blood
compartment was prevented by polymyxin B, a cationic peptide
that binds the lipid A moiety of LPS, we concluded that lipid A
fragments were crossing the membrane. Small-molecular-
weight fragments of LPS containing two fatty acids (/3-hydroxy-
myristic acid) linked to phosphorylated and acetylated glu-
cosamine disaccharides are the minimal structures required for
monocyte stimulation of IL-I and TNF production [27]. Al-
though the molecular weight of these fragments is approxi-
mately 2000 daltons, their three-dimensional structure and ionic
interactions with dialysis membranes are more indicative of
their ability to penetrate the membrane than is their calculated
molecular size.
The passage of endotoxin-like IL-i-inducing substances into
the blood compartment is supported by studies showing a
similar passage of radiolabeled LPS added to the dialysate
compartment into the blood circuit [28, 29]. Within 15 minutes,
between 1% and 5% of the radiolabeled LPS is found in the
blood side during in vitro hemodialysis. With time, the amount
increases to 10% to 20%. The molecular size of the labeled
fragments is low (2000 to 4000 daltons) and passage takes place
across a membrane made from cuprophane, polyamide, or
polysulfone. Compared with cuprophane membranes, high-flux
membranes are associated with greater amounts of LPS recov-
ered on the blood side. The amount of LPS that binds to the
membranes also depends on the type of polymer, with cu-
prophane binding the least. Using radiolabeled IL-i or TNF,
similar studies have shown that the binding of cytokines de-
pends on the polymer material. For example, AN69 binds IL.l
and TNF, whereas cuprophane does not [30].
The experimental data showing the passage of biologically
active as well as radiolabeled fragments of LPS from the
dialysate into the blood compartment do not agree with LAL
results I cited earlier. Even using high-flux membranes, passage
of LAL reactive materials does not take place, but radioactive and
cytokine-inducing fragments do cross into the blood compart-
ment. Studies suggest that fragments of LPS activate monocyte
cytokine production without being reactive in the LAL [31].
Another explanation is that plasma proteins "capture" LPS
and make it available for cytokine induction from mononuclear
cells, whereas LPS bound to such plasma proteins is nonreac-
tive in the LAL. Lipoproteins bind LPS, but this binding
reduces cytokine as well as LAL reactivity. On the other hand,
the recently cloned hepatic LPS-binding protein binds LPS and
facilitates the induction of IL-i and TNF in conjunction with
the phenotypic antigen or monocyte surface antigen known as
CD18. The LPS bound to the LPS-binding protein is, in fact,
non-reactive in the LAL. Another explanation for the failure of
LAL reactivity to correlate with induction of cytokines in the
blood compartment is based on the observation that non-
endotoxic microbial products are potent inducers of IL-i and
TNF. One such candidate that is supported by experimental
and clinical findings is the pseudomonas exotoxin [32]. In
summary, I believe that the weight of evidence favors the
concept that endotoxin fragments can cross dialysis mem-
branes, retain their biologic activity, and induce monocytes to
produce cytokines.
priming event
LPS
Acetate
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Role of complement activation in cytokine production. The
concept that monocytes become activated on the dialysis mem-
brane by factors such as CSa generation or the intrinsic nature
of the dialysis material is well supported by experimental
evidence using in vitro methods. In a typical experiment,
freshly obtained mononuclear blood cells are incubated with
various dialysis membranes, and the amount of IL-i produced
as a result of this activation is measured [30]. It is clear that
some membranes produce "wash materials" (for example,
LAL-reactive material) that, in the absence of serum factors, do
not lead to IL-i synthesis [33]. However, in the presence of
serum, these materials stimulate monocyte IL-i production in
vitro [34].
Considerable attention has focused on complement activa-
tion, especially because two of the complement products, C5a
and C3a, stimulate cytokine synthesis when purified from
human plasma [35]. New data cloud this issue because recom-
binant C5a, while possessing neutrophil activating properties,
does not trigger appreciable IL-l or TNF synthesis [36]. This
issue is not yet resolved, as recombinant C5a is not glycosy-
lated, whereas natural C5a is. Nevertheless, there seems to be
an important synergism between C5a and endotoxin in the
generation of cytokines, regardless of whether the C5a is
recombinant or natural [37]. For example, recombinant C5a
stimulates IL-I and TNF gene expression without significant
translation into cytokine protein [36], but in the presence of
substimulatory concentrations of endotoxin (5—10 pg/mI) in a
serum-free culture, the addition of recombinant C5a amplifies
the signal and causes IL-i and TNF synthesis [38].
When human blood is circulated in the blood compartment of
a hollow-fiber cuprophane dialyzer, transcription of DNA into
mRNA is apparent within 2 hours. In the absence of endotoxin
in the dialysate, however, there is no translation of mRNA into
IL-I protein [39]. This mRNA is rapidly and efficiently trans-
lated when exposed to low concentrations of endotoxin [39].
Thus, a 2-hour hemodialysis session results in IL-l and TNF
mRNA synthesis, and the cell is considered "primed" for
subsequent cytokine synthesis. Several agents can provide the
"second signal" for triggering cytokine translation of the
mRNA into cytokines in these primed cells; these agents
include endotoxin or IL-I itself [36].
Circulating cytokine levels in hemodialysis patients. Experi-
ments with in vitro dialysis have established that activation of
blood compartment monocytes takes place when endotoxin or
other microbial products are present in the dialysate. But are
cytokines elevated in the circulation of patients undergoing
routine hemodialysis? The initial studies were based on the
standard thymocyte co-mitogenic proliferation bioassay for
IL-i [40]. These thymocytes respond to IL-I as well as IL-6;
moreover, the combination of IL-l and IL-6 is more active than
either cytokine alone in the assay, From studies on patients not
on dialysis, we had learned that to measure IL-I activity in
human plasma, it was necessary to chromatograph the sample
over a gel-filtration column and measure IL-l activity in each
eluting fraction [41]. This chromatographic step removed circu-
lating factors that inhibited thymocyte proliferation in response
to IL-l; these factors usually eluted in a broad peak with
molecular weights of 20 to 50 kD. Employing these methods,
several groups independently demonstrated that patients under-
going routine dialysis using regenerated cellulose membranes
had evidence of elevated IL-l levels before a dialysis session; in
some studies, patients had a further increase of IL-l at the end
of the procedure [40, 42—45]. Elevations of IL-6 also have been
reported in patients treated with chronic hemodialysis but not in
patients with severe renal failure not undergoing dialysis [46,
47]. Subsequently, several groups showed that some of the IL-l
bioactivity was indeed IL-l by employing specific immunore-
active assays. Others, however, have failed to show elevated
IL-i or TNF in the plasma of hemodialysis patients, even using
optimal methods of detection and extraction [47, 48].
Bioassays are highly sensitive and are also affected by
synergistic effects between cytokines. As such, there could be
low levels of both IL-l and IL-6 by independent radioimmuno-
assay or ELISA assays, but together they could stimulate T- or
B-cell proliferation in a bioassay. ELISA assays are based on
recognition of a single antigenic epitope, and cytokines that
bind to a2-macroglobulin might not have these epitopes avail-
able for detection. During experimental endotoxemia in hu-
mans, IL-i and TNF are only transiently elevated [49, 50] and
multiple measurements are required to detect elevated levels of
cytokines in the circulation [51]. In general, the levels reported
for bioassayable cytokines in hemodialysis patients have not
been high; in fact, even humans undergoing strenuous exercise
have higher levels. One factor that might contribute to reducing
cytokine production in hemodialysis patients is poor nutrition.
Anemia appears to be another factor. Hemodialysis patients
treated with erythropoietin had a fivefold increase in the pro-
duction of TNF, interferon, colony-stimulating factors, and
IL-2 from mononuclear cells stimulated in vitro. Interestingly,
patients with severe renal failure who were not treated with
hemodialysis did not show evidence of elevated IL-l levels [44].
The conclusion is that the dialysis procedure leads to IL-i
production but that renal failure per se does not.
In response to inflammation, the host triggers counterregula-
tory mechanisms that tend to blunt the response. Increased
binding proteins might be involved in blunting the response to
cytokines. For example, a2-macroglobulin binds IL-I and IL-6;
the soluble TNF binding proteins are actually the soluble TNF
receptors [52]. In patients with burns, the amount of IL-l that
can be extracted from the plasma is less than that extracted
from the plasma of healthy subjects [51]. Plasma from hemodi-
alysis patients contains more inhibitory activity than does
plasma from healthy controls [53].
Production of cytokines by mononuclear cells from chronic
hemodialysis patients. Circulating mononuclear cells of pa-
tients undergoing chronic hemodialysis show signs of activa-
tion. This phenomenon has been demonstrated by removing
blood from the patients before or after each dialysis session and
measuring the amount of IL-l present in the mononuclear cells
immediately after isolation or after an overnight incubation. In
contrast to mononuclear cells removed from healthy human
subjects, mononuclear cells from patients on dialysis contain
IL-l [45, 54—57]. Using methods that include the polymerase
chain reaction, we found that peripheral blood mononuclear
cells isolated from more than 100 healthy subjects contain no
mRNA for IL-I [36, 39, 58—60]. Even after 24 hours of incuba-
tion, no evidence exists of IL-I synthesis in the mononuclear
cells of healthy donors [61—63]. However, incubation of mono-
nuclear cells from patients undergoing chronic hemodialysis in
the absence of exogenous stimuli results in spontaneous IL-I
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production [55—57]. When these cells are stimulated with fern-
tomolar concentrations of LPS, they produce as much as
fivefold more IL-I than do mononuclear cells from normal
subjects [45, 54—57, 64]. Similar results have been reported for
the production of TNF and IL-6 [64—66].
Thus, these studies demonstrate that patients treated with
hemodialysis have circulating mononuclear cells in a chronic
state of activation. This phenomenon also has been observed in
patients with sepsis, rheumatoid arthritis, and Kawasaki's
syndrome (reviewed in Ref. 60). Using a model of strenuous
exercise in healthy human volunteers, one can best assess
activation of IL-l production not from the circulating plasma
but rather from the circulating mononuclear cell population. As
in hemodialysis patients, there is an increase in the amount of
IL-l/3 and TNFa produced in vitro from mononuclear cells
stimulated with a femtomolar dose of LPS [67]. In fact, the
increased synthesis of mononuclear cells from these volunteers
24 hours after strenuous exercise correlated (P < 0.05) with
urinary 3-methylhistidine excretion, a marker of increased
muscle tissue breakdown [67].
Although it is often said that patients with chronic uremia do
not manifest fever when compared with nonuremic patients
with the same degree of infection, there is no laboratory
evidence that the uremic state suppresses the synthesis of
pyrogenic cytokines. In fact, from the data I have cited, just the
opposite seems to be the case. When studied using specific
radioimmunoassays, these and other results demonstrate that
there is no intrinsic defect in the synthesis of IL-l from the
mononuclear cells of uremic patients [68]. If caution is taken
not to introduce materials containing endotoxins, there is no
evidence of IL-l synthesis during 24 hours of culture of
mononuclear cells from healthy individuals [61]. Thus, patients
whose cells produce IL-I during culture are assumed to have an
ongoing pathologic process that activates gene expression for
IL-I in vivo, Dialysis appears to be such an in-vivo stimulus,
whereas severe renal failure itself is not.
Recently, support for the concept that monocytes are chron-
ically activated in hemodialysis patients has emerged via the
measurement of gene expression for IL-i and TNF in cells
passing through the dialyzer. Mononuclear cells removed from
the arterial inlet of the dialyzer contain a small but significant
amount of IL-l/3 and TNFa [69, 70]. However, after 5 minutes
of hemodialysis through a new cuprophane dialyzer, the mono-
nuclear cells in the blood exiting the dialyzer have initiated
transcription and express large amounts of IL-l/3 and TNFa.
Interestingly, the mononuclear cells returning to the dialyzer
from the arterial side do not show evidence of IL-i or TNF gene
expression. Even after 4 hours of hemodialysis, there is no
evidence of increased gene expression in cells removed from
the arterial inlet, whereas the venous exit port continues to
show the presence of mRNA for the cytokines. The interpreta-
tion of these findings is that a single passage through a comple-
ment-activating membrane is sufficient to trigger transcription,
and that once activated to express the cytokine genes, the
mononuclear cells leave the circulation and do not return during
the dialysis session. After 48 hours, however, the circulating
pool of mononuclear cells shows signs of having been activated.
These activated mononuclear cells contain elevated intracellu-
lar levels of IL-l [56, 57].
Gene expression for IL-I and TNF is rapid in a variety of
cells, Within 5 minutes after exposure to LPS or a glass surface,
IL-1f3 and TNFr mRNA in human mononuclear cells is tran-
scribed. Protein synthesis lags; in the case of TNF, this lag is
relatively short (on the order of 15 to 30 minutes) [6]. On the
other hand, translation into protein and secretion of IL-l/3 is
delayed, and levels are not elevated for at least 2 hours [59].
This delay is reflected in the appearance of the respective
cytokines in the circulation [50]. It is also reflected in the
release of these cytokines from stimulated mononuclear cells in
vitro [201. Induction of cytokine gene expression depends on
the polymer material of the dialyzer. Noncomplernent activat-
ing membranes do not stimulate cytokine genes [69], and this
lack also was observed during in vitro experimental hemodial-
ysis [39].
Cytokine production can be dissociated into two steps: (1)
mRNA synthesis and (2) translation of this mRNA into the
synthesis of protein; each event requires a separate signal [59].
Thus, in patients undergoing routine hemodialysis with a Cu-
prophane membrane, "priming," as evidenced by the presence
of mRNA, takes place even in the absence of contaminated
dialysate. The "primed" cell emanating from the dialyzer, for
example, can either degrade its mRNA without translation into
cytokine protein, or this cell can receive a second signal from
ongoing infection or illness. If such a second signal is encoun-
tered, this results in synthesis of the cytokine. A second signal
such as endotoxin can be provided by intestinal tissues, for
example. But the most likely source of a second signal is the
dialysate itself. Human mononuclear cells "primed" by expo-
sure to recombinant C5a produced more IL-i and TNF when
exposed to low concentrations of LPS (5 to 10 pg/mI) [36, 381.
It is unclear where the mRNA-primed mononuclear cells
leave the circulation during the hours of hemodialysis. A large
pooi of cells could be adhering to endothelium, particularly in
the lung, but receptors and adhesion molecules also could
attract activated monocytes to the synovium or other tissues.
Providing the patient with pyrogen-free dialysate could be an
important change in hemodialysis therapy, because it reduces
the chance of a second signal by LPS when complement
activation takes place. It is still unclear whether there is any
role for microbial products in providing a second signal when
the concentration of toxins in dialysate is low. It is more likely
that a second signal for translation of the primed cell's mRNA
into the cytokine protein can come from associated illnesses of
the hemodialysis patient.
Mechanisms of blocking IL-i and TNF
Although measuring in vitro production of cytokines in cells
removed from patients with various disease processes, includ-
ing chronic hemodialysis, is a worthwhile experimental ap-
proach, such determinations can give misleading clinical infor-
mation about the patient. In response to a variety of stimuli, the
same cells synthesizing IL-I and TNF also produce molecules
that block the action of these potent inflammatory cytokines.
The IL-i receptor antagonist (IL-Ira) and the soluble TNF
receptors (sTNFR) are examples of these blocking agents. The
IL-lra is an effective inhibitor of IL-I on nearly an equimolar
basis, by occupying the IL-i receptors without agonist activity;
the sTNFRs bind TNF, thus preventing TNF from interacting
with its cell-surface receptors. It is presently unknown how
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much IL-ira or sTNFR is produced in cells from patients
undergoing chronic hemodialysis.
Naturally occurring inhibitors of IL-i activity. Lipoproteins,
lipids, and s2-macroglobulin are examples of naturally occur-
ring substances that inhibit IL-I activity, but these molecules
also inhibit other cytokines, such as IL-6 and IL-2. Some
polypeptides specifically inhibit IL-i and have been called
"IL-I inhibitors." These inhibitors have been detected in the
serum of humans injected with bacterial endotoxin [71], in the
urine of febrile patients [72], in plasma following hemodialysis
[53], in supernatants of human monocytes adhering to IgG-
coated surfaces [73], and in the urine of patients with monocytic
leukemia [74], The IL-i receptor antagonist originally was
called the "IL-l inhibitor" [74, 75]; it was a 23 to 25 kD protein
purified from the urine of patients with monocytic leukemia
[74—76]. Natural IL-i inhibitor blocked the ability of IL-i to
stimulate synovial cell PGE2 production and thymocyte prolif-
eration; it also decreased insulin release from isolated pancre-
atic islets [74, 75, 77, 78]. The "IL-I inhibitor" blocked the
binding of IL-l to receptors on T-cells and fibroblasts but did
not affect the binding of TNF or IL-2 to their receptors [75, 77],
The IL-I inhibitor also did not bind to IL-i itself, unlike TNF
inhibitors, which also were isolated from the urine [52]. Thus,
the IL-i inhibitor was a competitive inhibitor of IL-i/IL-1R
interaction.
Using the IL-i inhibitor purified from adherent monocytes
[73, 79], two groups cloned the molecule [80, 81]. The cDNA
sequence codes for a polypeptide of approximately 17 kD with
a 26% amino acid homology to IL-113 and a 19% homology to
IL-la. Conserved amino acids revealed a41% homology of the
IL-Ira to IL-1/3 and 30% to IL-la.
Similar to the naturally occurring IL-I urinary inhibitor [75],
the recombinant IL-i inhibitor competes with the binding of
IL-I to its cell-surface receptors. Because of its sequence
homology and mode of activity, the IL-I inhibitor was renamed
the IL-I receptor antagonist (IL-Ira). The IL-lra blocks IL-i
activity in vitro and in vivo. In vitro, the IL-Ira appears to
occupy the IL-iRtI on T-cells and fibroblasts with nearly the
same affinity as that for bona fide IL-I but without demonstra-
ble agonist activity [79]. The human IL-ira also blocks the
binding of IL-I to human cells bearing the IL-iRtIl such as
neutrophils and B-cells [82] as well as human peripheral my-
elomonocytic leukemia cells [83]. Using murine T-cells (IL-
IRtI), the human IL-Ira blocks the binding of IL-i at nearly
equimolar comcentration; however, a 10- to 50-fold molar
excess of the IL-ira is required to block the binding of human
IL-I to human type II receptor-bearing cells [82].
The recombinant IL-ira blocks the activity of IL-I in various
animal models of disease. Rabbits [84] or baboons (Moldawer
L, personal communication) injected with IL-i develop hypo-
tension that can be prevented by the prior administration of the
IL-lra. However, a larger question remains: what effect does
specific blockade of IL-I have during acute or chronic disease,
when several cytokines are produced?
The administration of the IL-ira prevents death from LPS in
rabbits [841. The intravenous injection of E. coli into rabbits
produces several parameters of the septic shock syndrome,
namely, hypotension, decreased systemic vascular resistance,
leukopenia, thrombocytopenia, and tissue damage. When rab-
bits were pretreated with the IL-ira, however, only transient
and mild hypotension occurred, whereas hypotension was
severe and sustained, and the mortality rate was 50% in control
rabbits [85]. Also, the number of tissue-infiltrating neutrophils
was reduced. In these studies, the circulating levels of TNF and
IL/3 were unchanged. These results suggest that TNF is respon-
sible for the initial fall in blood pressure but that IL-I plays an
essential role in the progression of shock.
Data support a role for IL-i in the pathogenesis of colitis;
rabbits injected with soluble immune complexes developed
inflammatory cell infiltration, edema, and necrosis of the lower
colon. When rabbits are treated with the IL-ira, however, this
response decreases markedly [86]. In addition, PGE2 was
decreased in the rectal lumen even though IL-I tissue levels
were unchanged [87]. These data demonstrate that blockade of
IL-l prevents the onset and development of the inflammatory
lesion in this model of immune complex-induced colitis.
An autocrine role for IL-i has been proposed in leukemia, in
which IL-l production by leukemic blasts is uncontrolled and
results in production of colony-stimulating factors. The colony-
stimulating factors in turn drive proliferation of the cells.
Antibodies to human IL-Ip reduce the spontaneous prolifera-
tion and colony-stimulating activity production ofjuvenile-type
chronic granulocytic [88] and acute myelogenous leukemia cells
[89]. The IL-ira blocks the spontaneous proliferation as well as
spontaneous production of granulocyte-macrophage colony-
stimulating factor, IL-i, and IL-6 in peripheral blood- or
bone-marrow-derived acute myelogenous leukemia cells from
more than 25 patients [83]. When IL-Ira was removed after a
48-hour exposure, the leukemic cells died during a subsequent
72-hour incubation.
The IL-Ira blocks IL-l-induced thymocyte proliferation as
well as IL-I-induced synovial cell PGE2 synthesis and collage-
nase synthesis from chondrocytes. The IL-ra also blocks the
production of IL-i-induced IL-i, TNF, and IL-6 from human
peripheral blood mononuclear cells as well as from purified
monocytes [90]. In a rabbit model of meningeal inflammation,
the IL-ira blocks cerebrospinal pleocytosis induced by cere-
broventricular IL-I [91]. This effect requires a 5000-fold molar
excess of IL-ira to block 90% of the IL-i-induced pleocytosis.
A similar study has shown that intracerebroventricular injection
of 100 pg of the IL-Ira (10,000-fold excess) blocks non-rapid-
eye-movement sleep and fever induced by 10 ng of IL-i13 given
by the same route [92]. Systemic injection of the IL-ira at
100-fold molar excess blocks 95% of the fever induced by the
intravenous injection of IL-i in rabbits [93]. Administration of
IL-ira to rats with adjuvant arthritis has reduced the severity of
the joint lesions.
Soluble IL-JR and TNFR proteins. Another mechanism for
specifically blocking cytokines in disease states is the use of
soluble receptors. The extracellular domain of the IL-IRtI has
been expressed and shown to bind both forms of IL-i. When
recombinant soluble IL-lRtI was given to mice undergoing
heart allograft rejection, the survival rate of the heterotopic
grafts increased. Lymph nodes directly injected with allogeneic
cells manifest reduced hyperpiasia with the use of the soluble
IL-iRti [94]. The effects of the soluble type-I receptor probably
are due to decreased inflammation rather than to decreased
immunoresponsiveness.
Like IL-I, there are two cell surface receptors for TNF [95],
but unlike IL-i receptors, soluble TNF receptors are found
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naturally in the urine of normal humans. The soluble TNF
receptors were initially described as specific TNF binding
proteins and later shown to represent the shed forms of the
extracellular segments of TNF receptors [52]. Soluble TNF
receptors bind TNF with affinities equal to those of the intact
receptors found on cells, and these receptors render TNF
incapable of agonist activity. The use of soluble TNF receptors
holds promise in the treatment of septic shock and other disease
states in which TNF plays a pathologic role.
Although there is now laboratory as well as clinical evidence
that production of IL-I and TNF is triggered by complement-
and non-complement-activating membranes, we still have no
proof that any acute or chronic change in patients undergoing
hemodialysis is due to cytokine induction. However, the IL-ira
and sTNFR are highly specific in what they can block. As I
said, specific blockade of IL-I or TNF dramatically reduces
disease severity. If IL-i or TNF is affecting blood pressure or
other parameters of the hemodialysis syndrome, then adminis-
tration of either the IL-lra or sTNFR should alter the degree of
the response. The IL-Ira and the sTNFR may prove to have a
therapeutic role during or after a hemodialysis session in
blocking the potential action of these cytokines in the patho-
genesis of dialysis-related hypotension. In a similar scenario,
these specific agents can be used to test the hypothesis that
dialysis-related fever is cytokine-derived. The long-term use of
either the IL-ira or sTNFR for complications of hemodialysis,
such as carpal-tunnel syndrome or susceptibility to infection, is
also a possibility. However, it is my opinion that these agents
first should be established as useful for treating rheumatoid
arthritis and other chronic inflammatory diseases before they
are tried for amelioration of untoward effects in dialysis pa-
tients.
Questions and answers
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): Thank you, Dr.
Dinarello, for a beautiful tour of the complex world of the
cytokines, or microendocrinology as I prefer to call it. I still
have difficulty in putting all the interleukins and other cytokines
together. Is there a flow diagram, analogous to the one for the
clotting system, that tells how one interleukin interacts with
another?
DR. DINARELLO: No, unfortunately there isn't such a dia-
gram. However, the lucky thing for us is that interleukin-l was
named for interleukin-l and not interleukin 3, or 4, because it
turns out that there is a bit of logic to it. lnterleukin-l initiates
the cascade of other cytokines. For example, interieukin-l
stimulates the gene expression for interleukins 2, 3, 4, 5, 6, 7,
and 8. When these "factors" were named, this information was
unknown, as was the existence of so many other cytokines.
However, other cytokines do not have interleukin nomencla-
ture. For example, tumor necrosis factor is very much like IL-I
in its various biologic properties. At present, one should
remember that IL-I and TNF share most of their inflammatory
properties, and that both are capable of inducing the synthesis
of other cytokines. The logic stops there. It's very difficult to
say which of the myriad cytokines produced during disease
dominates, and how these cytokines affect clinical outcome. If
you have a lot of interleukin-l and very little interleukin-lO, you
might have an inflammatory state; if you have a lot of interleu-
kin-lO and very little interieukin-l, maybe irnmunosuppression
will dominate. Further, cytokines are produced by nearly every
cell under conditions that we associate with disease.
I don't know when the numbers are going to stop. A new
cytokine is often called an "interleukin" because its discovery
is likely to be announced in The Wall Street Journal by a
biotechnology company. Perhaps the magical quality of the
name "interleukin" comes from the study of IL-2 treatment in
cancer. There is a good reason for a new molecule's being
called an interleukin, however. These cytokines often possess
several biologic properties, and the predominant biologic prop-
erty is not always known at the time of its molecular cloning;
calling the molecule an interleukin is a good compromise.
DR. HARRINGTON: You referred to the severe hypotension
that accompanies the administration of IL-I. What do we know
about the interaction of IL-i with the new micro-micro hor-
mones, that is, endothelium-derived relaxing and constricting
factors?
DR. DINARELLO: In innovative work, Beasiey applied IL-I to
smooth muscle cells [961. The IL-i prevented vasoconstriction,
acting as a paralyzing factor for vasoconstricting hormones.
The mechanism seems to be an IL-i-induced generation of
nitric oxide, formerly called endothelial relaxation factor.
DR. ANDREW KING (Division of Nephrology, New England
Medical Center): I can comment on that. Beasley has incubated
aortic vascular smooth muscle cells with IL-i and found a
substantial increase in cellular cyclic GMP, a marker of nitric
oxide production [96]. Similar results were obtained by using
TNF.
DR. DINARELLO: Do the endothelial cells have to be stripped
away for this to work?
DR. KING: These studies were performed using vascular
smooth cells in culture. I should add that Phil Marsden ob-
served similar findings in cultured mesangial cells exposed to
TNF (personal communication). I have a question as well. Do
these cytokine antagonists, such as the IL-i receptor antago-
nist, have any pressor effects in animals or humans?
DR. DINARELLO: No. The cytokine antagonists block shock
in animal models very beautifully and prevent hypotension and
death in baboons and rabbits. We have not observed any
pressor or agonist activity. We have begun the first clinical trial
of the interleukin-l antagonist in healthy volunteers [971. We've
given as much as 10 mg/kg of IL-Ira and seen no increase in
blood pressure. In humans, IL-Ira has no agonist-like activities.
Therefore, we are poised for clinical studies because we'd like
to find out whether the administration of IL-ira will reduce
dialysis-associated hypotension.
DR. JEROME P. KASSIRER (Editor-in-Chief, New England
Journal of Medicine, Boston, Massachusetts): How significant
are the benefits to the patient of introducing membranes and
dialysates free of contaminating endotoxins and exotoxins? I
imagine that the costs of "cleaning up" the system would be
quite high. Are the benefits worth the expense?
DR. DINARELLO: The cuprophane membrane is inexpensive
and has proved its ability to block endotoxins and other
microtoxins even with repeated use. The need for "cleaning
up" the dialysate is at present a hypothetical consideration
based on in vitro studies using large-pore membranes and
extraordinarily high levels of dialysate contamination. The
potential danger comes with membranes that have larger pore
sizes for clearing more middle molecules. The larger pores
increase the chances of back-filtration and entry of toxins from
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the dialysate. Although this actually has occurred with this type
of membrane in a few clinical situations, it is not a major
problem at present. Most centers now use reverse-osmosis
water, and this change has reduced dialysate toxins consider-
ably. I would say 90% of the potential problems from contam-
inated dialysate have been eliminated. With the increasing use
of larger-pore membranes, however, the chance of toxemia
increases. On-line ultrafiltration of the dialysate is not expen-
sive. The ultrafiltration membranes can be used over several
months,
DR. ANDREW S. LEVEY (Division of Nephrology, New En-
gland Medical Center): Your work has shown that we can
measure cytokine levels in plasma, identify cytokine gene
transcripts in white cells taken from patients, and that dialysis
membranes might contribute to the cytokine levels in blood and
gene expression in multiple ways. We now need to select the
appropriate measurements to assess clinical outcomes. Carpal-
tunnel syndrome and bone and joint abnormalities take a long
time to develop. How are we going to begin to evaluate the
importance of dialysis membrane-induced alterations in cyto-
kines in the clinical setting?
DR. DINARELLO: Patients with severe renal failure do not
manifest the same cytokine increases as do dialysis patients.
Carpal-tunnel syndrome is a good example: it has the same
incidence in hemodialysis and CAPD patients, but CAPD
patients don't use dialysis membranes. Clinical manifestations
such as carpal-tunnel syndrome might not be related to cyto-
kines but to beta2-microglobulin. The only connection we can
make is that TNF and IL-l increase class-I MHC expression. In
terms of clinical parameters, I don't think there is an easily
identifiable syndrome that specifically reflects cytokine induc-
tion by hemodialysis membranes. If we designed a membrane
that doesn't induce much gene expression for cytokines, such
as polysulfone, at least we are not stimulating monocytes 3
times per week. At present, we simply assume that the conse-
quences of that stimulation have adverse effects. When we have
more data on interleukin-l antagonists and TNF-binding pro-
teins in a couple of years, I might be able to say, "Dr. Levey,
these studies have shown that blocking IL-l and TNF have
really made big differences in some diseases." Then you would
have to think twice about using hemodialysis membranes that
induce cytokines. If it turns out that we haven't made any major
reversals of disease processes with these specific antagonists,
we can conclude that the body effectively deals with interleu-
kin-I and TNF gene expression as it does when you run up a
flight of stairs. Dr. Joseph G. Cannon showed many years ago
that running around the Charles River is just as bad as a dialysis
session in terms of cytokine induction [98]. For many people in
this room, running around the Charles River is preferable to
having hemodialysis. There's another side of this. Every time a
woman ovulates she has enough inflammation to stimulate these
cytokines, yet she deals with it. The healthy body deals with
transient expression of these cytokines. Does the dialysis
patient as well?
DR. KLEMENS MEYER (Division of Nephrology, New En-
gland Medical Center): Our patients tell us that they feel
"washed out" after they are dialyzed. Do you think that this
feeling has anything to do with cytokines?
DR. DINARELLO: Yes, that's what the patients say when they
receive interleukin- 1 injections—that they are completely
washed out.
DR. MEYER: Is there anything we can do about it?
DR. DINARELLO: I think it would be appropriate to give the
interleukin-l receptor antagonist or soluble TNF receptor in a
controlled clinical situation and see whether these patients
improve.
DR. PAUL KURTIN (Division of Nephrology, New England
Medical Center): My first question refers to blood pressure
changes during dialysis. We know that many patients tolerate
dialysis with bicarbonate better than with acetate. Most of the
in vitro work that you've presented has been done using an
acetate dialysate. Do you have any in vitro data using bicar-
bonate dialysate?
DR. DINARELLO: Acetate was the preferred dialysate at the
time of our studies, so we have done all our experiments using
an acetate dialysate.
DR. KURTIN: All high-flux dialysis systems use bicarbonate
baths. Patients tolerate this type of dialysis hemodynamically
better with bicarbonate, so you'll be seeing more bicarbonate
baths in the future. Also, there is a small percentage of patients
who are acetate intolerant, and they also require bicarbonate
baths.
My second question concerns the temperature of your in-
vitro model experiments. Were they carried out at room tem-
perature? Studies suggest that patients experience less hypo-
tension if they are dialyzed against a cooler dialysate [99]. Do
you have evidence of that temperature dependence?
DR. DINARELLO: Cytokine induction is temperature sensi-
tive.
DR. KURTIN: There is growing interest in the possibility that
the dialysis procedure itself produces a catabolic effect and
contributes to the cachexia of dialysis patients. Because you
didn't mention catabolism, would you please comment on the
role of IL-I in the cachexia of patients on chronic dialysis?
DR. DINARELLO: Interleukin-l is a very potent anorexic
agent. In addition, in vitro data have shown that IL-i induces
muscle proteolysis [100]. Systemic injection of the cytokines is
far more potent in producing anorexia than in inducing loss of
mean body mass, however.
DR. JEFFREY GELFAND (Vice Chairman, Department of
Medicine, New England Medical Center): One of the important
points you made was that the stimulation of interleukin-l
production is not just an acute phenomenon associated with the
immediate dialysis period, but in fact a chronic, ongoing,
low-level increase in production. To a certain extent, we can
control our chronic production of interleukins with dietary
manipulations such as changes in intake of omega-3 fatty acids.
Would it not be reasonable to suggest a clinical protocol in
which the long-term effects of omega-3 fatty acids are examined
in this very situation?
DR. DJNARELIO: Some trials using omega-3 fatty acids have
studied the dialysis population, but the studies focused on
platelet adhesion and serum lipid profile changes. These studies
were too short to see a reduction of cytokine production.
Whether the introduction of omega-3 fatty acids is beneficial
won't be known until long-term trials have been completed.
DR. BRIAN J. G. PEREIRA (Division of Nephrology, New
England Medical Center): Would you address the issue of the
dialysis of preformed cytokines by increasing the pore size of
dialysis membranes? While this maneuver possibly clears the
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cytokines from the circulation, it also facilitates entry of endo-
toxins from the dialysate, which in turn stimulates cytokine
production.
DR. DJNARELLO: If you have sterile dialysate, there is no
problem with larger-pore membranes.
DR. PEREIRA: Having a sterile dialysate requires a high
degree of water purity and elimination of all bacteria, which
would involve a considerable escalation in the cost of dialysis.
I have another question. The use of platelet activating factor
(PAF) antagonists in experimental models of hyperacute rejec-
tion and xenograft rejection has been disappointing, because
other mediators take over the role of PAF in sort of a physio-
logic bypass pathway. It is therefore difficult to envision any
significant efficacy of specific antagonists. Do you agree that
antagonists of multiple cytokines will have to be employed?
DR. DINARELLO: Certainly the other cytokines lower blood
pressure [8]. It may be that the only way to effectively treat
shock is to give a combination of anti-ILl and anti-TNF.
DR. AJAY SINGH (Division of Nephrology, New England
Medical Center): As you know, immune mechanisms are the
predominant cause of almost all forms of glomerulonephritis
and of a large proportion of tubulointestinal nephritides. Have
you found that there are patients with certain diseases who are
more sensitive or more resistant to the efects of these dialysis
membranes?
DR. DINARELLO: We've not looked. It's a good question, but
there is an enormous variation in cytokine production levels in
the dialysis population. We've noticed this variation but have
made no attempt to see how this variation relates to the cause
of renal disease in this patient population.
DR. HARRINGTON: Occasionally, a patient with rheumatoid
arthritis ultimately develops secondary amyloidosis, just as the
chronic dialysis patient can develop a certain kind of amyloi-
dosis. Obviously there's a difference in the type of amyloidosis.
Do differences in cytokine production in these two types of
patients influence the type of amyloid produced?
DR. DINARELLO: Although the dialysis population is different
from rheumatoid patients in terms of the nature of the deposi-
tion material, in dialysis patients, the deposition is made of
beta2-microglobin [1011; in arthritis, the deposition is amyloid
protein, Both groups appear to have evidence of similarly
elevated IL-I production from their peripheral blood mononu-
clear cells in vitro. At this point, there do not seem to be any
differences in cytokine production between the two groups
despite the fact that their amyloid deposition material is quite
different.
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